Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Ascendis Pharma Stock: Behind The Stock Surge (NASDAQ:ASND)
Ascendis Pharma has more than tripled over the past two and a half years, driven by Yorvipath's blockbuster launch and Yuviwel's FDA approval. Yorvipath's rapid adoption and ongoing label expansion underpin robust revenue growth. Yuviwel-Skytrofa…
No, Rogers didn't take $14M as 'pharma lobbyist'
Michigan U.S. Senate candidate Abdul El-Sayed has centered healthcare in his campaign, championing Medicare for All and critiquing his opponents, both Democratic and Republican, on the issue. El-Sayed, a Democrat and former public health official…
Nifty holds above 24,350 at noon; IT, Pharma and Financials lead broad rally
Markets maintained firm gains through the first half of trade on Friday, with the Sensex up 539.09 points or 0.70 per cent at 78,041.21 and the Nifty 50 higher by 182.10 points or 0.75 per cent at 24,357.80, as of 12.55 PM. The session so far has…
Moscow's SEZ Pharma Players Pour 1.7× More Investments Into City's Economy
The top investor in January-March 2026 was a pharmaceutical company currently conducting clinical trials of a drug targeting 30 types of cancer. The resident company has also developed four biosimilars for the treatment of melanoma, non-small cell…
Pfizer's CEO Says His Company Has a 'Very Big Balance Sheet' to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant
Pfizer 's (PFE +1.84%) shares have significantly underperformed broader equities over the past three years. The company's reliance on its coronavirus portfolio has been a weakness, as vaccination rates have declined, while U.S. regulators have made…
USS Investment Management Ltd Boosts Position in Royalty Pharma PLC $RPRX
USS Investment Management Ltd increased its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 21.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.
Royalty Pharma (NASDAQ:RPRX) EVP Sells $5,652,000.00 in Stock
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Christopher Hite sold 100,000 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $56.52, for a total value of $5,652,000.00. Following…
Peak Rock Capital Buys Asembia As Specialty Pharmacy Industry Grows
The private equity firm Peak Rock Capital is buying Asembia, a fast-growing provider of services surrounding specialty pharmacy including distribution, group purchasing and technology connecting pharmacies, drug makers, patients and other…
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 9,099 Shares
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 9,099 shares of the business's stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $55.88, for a total value of $508,452.12. The…
Pictet Asset Management Holding SA Increases Stake in Royalty Pharma PLC $RPRX
Pictet Asset Management Holding SA raised its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 12.4% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned…
Stock markets take winning run to 3rd day
Benchmark equity indices Sensex and Nifty ended higher on Friday, extending their winning momentum to the third day running, amid a rally in IT stocks and a softer-than-expected US jobs data tempering expectations of near-term monetary tightening…
Medicine's Monopoly Problem
Tahir Amin started out wanting to play professional football in England. He found law instead, and specifically intellectual property law in the early 1990s, when the field was still new enough to feel cutting edge. After a decade of commercial IP…
GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH
Coverage and future reimbursement (effective August 10, 2026) secured for NASHnext, Labcorp's non-invasive blood-based diagnostic test powered by GENFIT's proprietary NIS4 technology Focuses on patients at highest risk, including those with…
Orion publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026
Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026 Orion will publish Half-Year Report for January–June 2026 on Friday, 17 July 2026 at approximately 12.00 noon EEST. The report and related…
Sensex, Nifty Extend Winning Streak on IT Stocks Rally, Global Rate Hopes
Indian benchmark equity indices, Sensex and Nifty, extended their winning streak for a third consecutive day, driven by a rally in IT stocks and global cues suggesting a more accommodative monetary policy after softer-than-expected US jobs data.
Receive a Daily briefing on Pharma Industry News
Get Started